Related Experiment Video
Updated: Dec 26, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
Christopher S Pauli1, Matthieu Conroy1, Brian D Vanden Heuvel2
1Institute of Cannabis Research, Colorado State University-Pueblo, Pueblo, CO, United States.
Abstract:
This review aims to present completed clinical trial data surrounding the medicinal benefits and potential side effects of the increasingly popular cannabidiol (CBD)-based drug products, specifically Epidiolex. The article is divided into two sections based on if the ailment being treated by this cannabinoid is classified as either physiological or neurological conditions. In addition to describing the current status, we also examined the different primary and secondary outcomes recorded for each study, which varies greatly depending on the funding source of the clinical trial. With the recent FDA-approval of Epidiolex, this review mainly focused on trials involving this specific formulation since it is the only CBD-based drug currently available to clinicians, although all other clinically trialed CBD(A) drugs were also examined. We hope this review will help guide future research and clinical trials by providing the various outcomes measured in a single review.
Related Concept Videos
Clinical Trials: Overview
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Preclinical Development: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

